Our kits take you from single cell or single nuclei suspensions through sequencing straight into biological insights.
Target 100s to 1000s of genes to analyze more samples with less sequencing.
Transform single cell sequencing output into understandable results.
Parse Biosciences provides researchers with the ability to perform single cell sequencing with unprecedented scale and ease.
A Seattle-based company with the mission of accelerating progress in human health and scientific research.
Customer interviews, single cell sequencing tips and tricks, and the latest updates from Parse Biosciences.
A list of upcoming conferences and webinars we are attending.
The latest news stories and press releases from Parse Biosciences.
Explore our library of resources to learn more about Evercode technology and some applications from leading researchers.
Download publications and posters featuring the Evercode technology in single cell research.
Explore datasets covering various applications and sample types or access product details.
Watch past webinars on Evercode technology and its applications.
Information and insight for the entire range of Parse Biosciences products.
At Parse Biosciences, we are providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease. Single cell RNA sequencing has already enabled breakthroughs in developmental biology, stem cell therapy, immunotherapy, and cancer treatments. Our foundational Evercode™ combinatorial barcoding technology is driving the next generation of discoveries.
Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research.
The people of Parse are curious, collaborative, and driven by purpose.
An estimated 1 billion people worldwide live with a neurological disorder, whether it be Alzheimer's, epilepsy, multiple sclerosis, or cancer, among others. A vibrant community of researchers is committed to further understand these disorders. Throughout the month of June, join us as we shine a light on these researchers and the unique ways they are using Parse Evercode WT single cell RNA sequencing to transform our understanding of the brain.
The SSI2023 meeting brings together immunologists at all career stages, from Ph.D. students to experienced senior scientists interested in various aspects of immunology. The Parse team will be there to talk about our products.
Join us for our satellite symposium at ESHG on Monday, June 12, 14:00 – 15:30 BST. Parse staff will be on hand to share information about our single cell platform at booth #134.
Alex cofounded Parse Biosciences and leads the organization as its Chief Executive Officer. Alex is an experienced leader and technologist with a track record of pushing innovation in next-generation sequencing, machine learning, and predictive models of biology. As a Commercialization Fellow at the University of Washington, Alex co-invented the single cell technology that inspired Parse’s foundational Evercode™ platform. Alex is an active technical leader and inventor with multiple publications in high-profile journals such as Cell and Science and several patents.
Alex received a Ph.D. in Electrical Engineering from the University of Washington and BSE in Electrical Engineering from the University of Michigan.
Charlie cofounded Parse Biosciences and leads as its Chief Technology Officer. Charlie is passionate about biology-based technology development, with over a decade of driving innovation in the field. Prior to Parse, he was at the University of Washington where he received several fellowships from the NIH and Fred Hutch Cancer Research Center. This work generated high-profile publications in Science and informed the core technology of Parse Biosciences. Previously, Charlie contributed to innovations in drug delivery and microscopy at the Wyss Institute at Harvard and the University of Pennsylvania.
Charlie received a Ph.D. in Bioengineering from the University of Washington and BSE in Biological Systems Engineering from Virginia Tech.
Britton serves as Chief Financial Officer at Parse Biosciences. Having worked in both emerging growth companies as well as large multinational organizations, Britton provides experienced financial leadership. He previously worked in Finance leadership positions at Genapsys, a DNA sequencing company; ArcherDX, a genomic analysis company; and later Invitae, after it acquired ArcherDX in October 2020. Prior, Britton held a diverse range of corporate finance roles with increasing responsibility at AstraZeneca, Genentech/Roche, and Royal Dutch Shell.
Britton holds an MBA from Rice University, a BS in Finance, and a BA in Business and Sustainability from Arizona State University.
